All In Biotech

Drug Trial Radar · NCT04939428

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19

Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,441 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,441

Actual

Start

Aug 11, 2021

Primary completion

Nov 16, 2022

Study completion Nov 16, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.

Conditions

  • Coronavirus Disease (COVID-19)

Interventions

  • MolnupiravirDrug

    Four molnupiravir 200 mg capsules taken by mouth.

  • PlaceboDrug

    Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14Time frame: Day 14
  2. Percentage of Participants With ≥1 Adverse EventTime frame: 29 days
  3. Percentage of Participants Discontinuing From Study Therapy Due to AETime frame: Up to 5 days

Locations

226 sites in 23 countries. Site status is shown where the registry gives one.

  • Cahaba Research, Inc. ( Site 2523)

    Birmingham, Alabama

  • The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2484)

    Mesa, Arizona

  • The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2448)

    Tucson, Arizona

  • Hope Clinical Research ( Site 2400)

    Canoga Park, California

  • Carbon Health ( Site 2515)

    Carlsbad, California

  • UCSF Fresno ( Site 2528)

    Fresno, California

  • ASCADA Research, LLC ( Site 2516)

    Fullerton, California

  • Marvel Clinical Research ( Site 2490)

    Huntington Beach, California

  • National Research Institute ( Site 2452)

    Los Angeles, California

  • Valley Clinical Trials Inc. ( Site 2406)

    Northridge, California

  • Carbon Health ( Site 2514)

    Oakland, California

  • University of California Davis ( Site 2497)

    Sacramento, California

  • Millennium Clinical Trials ( Site 2468)

    Simi Valley, California

  • Future Innovative Treatments, LLC ( Site 2471)

    Colorado Springs, Colorado

  • Emerson Clinical Research Institute ( Site 2457)

    Washington D.C., District of Columbia

  • Synergy Healthcare ( Site 2521)

    Bradenton, Florida

  • Accel Research Sites-DeLand Clinical Research Unit ( Site 2535)

    DeLand, Florida

  • Velocity Clinical Research, Hallandale Beach ( Site 2485)

    Hallandale, Florida

  • Indago Research and Health Center Inc ( Site 2412)

    Hialeah, Florida

  • Advanced Research For Health Improvement LLC ( Site 2436)

    Immokalee, Florida

  • Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2508)

    Miami, Florida

  • CDC Research Institute, LLC ( Site 2540)

    Port Saint Lucie, Florida

  • Clinical Research Trials of Florida ( Site 2402)

    Tampa, Florida

  • Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2425)

    Winter Park, Florida

  • Balanced Life Healthcare Solutions/SKYCRNG ( Site 2539)

    Lawrenceville, Georgia

  • Chicago Clinical Research Institute Inc ( Site 2454)

    Chicago, Illinois

  • Rush University Medical Center ( Site 2510)

    Chicago, Illinois

  • Southern Clinical Research Associates ( Site 2542)

    Metairie, Louisiana

  • MedPharmics, LLC ( Site 2443)

    Metairie, Louisiana

  • Institute of Human Virology ( Site 2504)

    Baltimore, Maryland

  • Centennial Medical Group ( Site 2435)

    Elkridge, Maryland

  • Jadestone Clinical Research, LLC ( Site 2530)

    Silver Spring, Maryland

  • Michigan Center of Medical Research ( Site 2445)

    Farmington Hills, Michigan

  • Michigan Center of Medical Research ( Site 2525)

    Lathrup Village, Michigan

  • Allina Health Infectious Diseases Research Clinic ( Site 2507)

    Minneapolis, Minnesota

  • Prime Health and Wellness/SKYCRNG ( Site 2538)

    Fayette, Mississippi

  • Quinn Healthcare/Skycrng ( Site 2537)

    Ridgeland, Mississippi

  • University of Missouri Hospital ( Site 2486)

    Columbia, Missouri

  • Mercury Street Medical Group PLLC ( Site 2476)

    Butte, Montana

  • University of Nebraska Medical Center ( Site 2430)

    Omaha, Nebraska

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.